ArticleEndocrine2026
The silent surden: Alexithymia and quality of life in acromegaly patients.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aim to investigate the potential link between the physical changes associated with acromegaly and the development of alexithymia, as well as its related psychopathological outcomes and impact on quality of life.
methodsThe study included 137 patient with acromegaly and 125 control group patients. Body Image Scale (BIS), Toronto Alexithymia Score-20 (TAS-20), Hospital Anxiety and Depression inventory (HAD), Short Form-36 (SF-36) and Acromegaly Quality of Life Scale (AcroQol) were used to the patients.
resultsIn the acromegaly group, TAS-20 total scores, as well as the Difficulty Identifying Feelings (DIF) and Difficulty Describing Feelings (DDF) subscale scores, were higher compared to the control group (51 vs. 44, p < 0.01; 16 vs. 12, p < 0.01; and 12 vs. 11, p < 0.01, respectively). In contrast, no notable difference was observed in the Externally Oriented Thinking (EOT) scores between the groups. The prevalence of alexithymia was markedly higher in individuals with acromegaly (16.7%) than in the control group (3.2%, p < 0.001). A positive correlation was found between alexithymia and both depression and anxiety scores (r = 0.469, p < 0.001; r = 0.377, p < 0.01, respectively). In contrast, alexithymia was negatively correlated with SF-36, AcroQoL and BIS (r = − 0.426, p < 0.01; r = − 0.465, p < 0.01; r = − 0.364, p < 0.01, respectively). Patients with acromegaly reported poorer body image and a higher rate of impaired body perception compared to control group (43.7% vs. 19.2%, p < 0.01).
conclusionThe present study demonstrates that alexithymia is more prevalent in patients with acromegaly compared to controls and often persists even after remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.